Journal List > J Korean Ophthalmol Soc > v.52(2) > 1008979

Kim and Kim: Effect of Mitomycin C and 5-Fluorouracil on Cultured Human Nasal Mucosa Fibroblasts

Abstract

Purpose

To investigate the effects of two antimetabolites, mitomycin C (MMC) and 5-fluorouracil (5-FU), on proliferation of cultured human nasal mucosa fibroblasts.

Methods

Human nasal mucosa fibroblasts were primarily cultured, and exposed to various concentrations of MMC and 5-FU for 5 minutes. Control fibroblasts were exposed to only DMEM media without the drugs. Effect of drugs on cell morphology was observed by phase-contrast microscopy. Cell viability and apoptosis were measured using MTT [3-(4,5-dime-thylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide] assay and Acridine orange/Hoechst (AO/HO) staining, respectively.

Results

In both experimental groups exposed to MMC and 5-FU, fibroblasts maintained standard spindle shape. The MTT assay showed that both MMC and 5-FU inhibited fibroblast proliferation in a dose dependent manner. AO/HO staining showed apoptotic cells in both experimental groups.

Conclusions

Both MMC and 5-FU have an antiproliferative effect on fibroblasts in vitro at least through induction of apoptosis. Therefore, adjuvant use of either MMC or 5-FU during endonasal dacryocystorhinostomy may improve the clinical outcome by inhibiting proliferation of the nasal mucosa.

References

1. Caldwell GW. Two new operations for the radical cure of obstruction of the nasal duct with preservation of the canalicuoli and an incidental description of a new lacrimal probe. NY Med J. 1893; 57:581.
2. McDonogh M, Meiring JH. Endoscopic transnasal dacryocystorhinostomy. J Laryngol Otol. 1989; 103:585–7.
crossref
3. Woog JJ, Kennedy RH, Custer PL, et al. Endonasal dacryocystorhinostomy: a report by the American Academy of Ophthalmology. Ophthalmology. 2001; 108:2369–77.
4. Lee HC, Chung WS. Success rate of endonasal Dacryocystorhinostomy. J Korean Ophthalmol Soc. 1996; 37:211–8.
5. Lee SH, Chung WS. Long term surgical efficacy of endonasal dacryocystorhinostomy. J Korean Ophthalmol Soc. 2000; 41:307–13.
6. Lee TS, Kim JS, Kim JK. The effect of double silicone tube intubation on surgical outcome of endonasal dacryocystorhinostomy. J Korean Ophthalmol Soc. 2002; 43:2089–94.
7. Allen K, Berlin AJ. Dacryocystorhinostomy failure: association with nasolacrimal silicone intubation. Ophthalmic Surg. 1989; 20:486–9.
crossref
8. Zolli CL, Shannon GM. Dacryocystorhinostomy: a review of 119 cases. Ophthalmic Surg. 1982; 13:905–10.
crossref
9. McLachlan DL, Shannon GM, Flanagan JC. Results of dacryocystorhinostomy: analysis of the reoperation. Ophthalmic Surg. 1980; 11:427–30.
10. Tarbet KJ, Custer PL. External dacryocystorhinostomy. Surgical success, patient satisfaction, and economic cost. Ophthalmology. 1995; 102:1065–70.
11. Walland MJ, Rose GE. Factors affecting the success rate of open lacrimal surgery. Br J Ophthalmol. 1994; 78:888–91.
crossref
12. Kao SC, Liao CL, Tseng JH, et al. Dacryocystorhinostomy with intraoperative mitomycin C. Ophthalmology. 1997; 104:86–91.
crossref
13. Yalaz SC, Firinciogullari E, Zeren H. Use of mitomycin C and 5-fluorouracil in external dacryocystorhinostomy. Orbit. 1999; 18:239–45.
crossref
14. Kim JH, Kim KS, Yoon HC, et al. Anti-adhesive effect of GUARDIX-SL® after endoscopic sinus surgery. Korean J Otolaryngol- Head Neck Surg. 2005; 48:1478–83.
15. Lee TS, Lee KC. The effect of Mitomycin-C eyedrop on pre-vention of internal ostium obstruction after endonasal dacryocystorhinostomy. J Korean Ophthalmol Soc. 1998; 39:1915–20.
16. Ugurbas SH, Zilelioglu G, Sargon MF, et al. Histopathologic effects of mitomycin-C on endoscopic transnasal dacryocystorhinostomy. Ophthalmic Surg Lasers. 1997; 28:300–4.
crossref
17. Zilelioğ lu G, Uğ urbaş SH, Anadolu Y, et al. Adjunctive use of mitomycin C on endoscopic lacrimal surgery. Br J Ophthalmol. 1998; 82:63–6.
18. Roozitalab MH, Amirahmadi M, Namazi MR. Results of the application of intraoperative mitomycin C in dacryocystorhinostomy. Eur J Ophthalmol. 2004; 14:461–3.
crossref
19. Iliff CE. A simplified dacryocystorhinostomy. 1954-1970. Arch Ophthalmol. 1971; 85:586–91.
20. Watts P, Ram AR, Nair R, Williams H. Comparison of external dacryocystorhinostomy and 5-fluorouracil augmented endonasal laser dacryocystorhinostomy. A retrospective review. Indian J Ophthalmol. 2001; 49:169–72.
21. Hu D, Sires BS, Tong DC, et al. Effect of brief exposure to mitomycin C on cultured human nasal mucosa fibroblasts. Ophthal Plast Reconstr Surg. 2000; 16:119–25.
crossref
22. Givens KT, Kitada S, Chen AK, et al. Proliferation of human ocular fibroblasts. An assessment of in vitro colorimetric assays. Invest Ophthalmol Vis Sci. 1990; 31:1856–62.
23. Senderoff RI, Weber PA, Smith DR, Sokoloski TD. Evaluation of antiproliferative agents using a cell-culture model. Invest Ophthalmol Vis Sci. 1990; 31:2572–8.
24. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983; 65:55–63.
crossref
25. Mpoke SS, Wolfe J. Differential staining of apoptotic nuclei in living cells: Application to macronuclear elimination in Tetrahymena. J Histochem Cytochem. 1997; 45:675–83.
26. Gilman AG, Goodman LS, Gilman A. The Pharmacological Basis of Therapeutics. 6th ed.New York: Macmillan Publishing Co.;1980. p. 1295–300.
27. Dushinski R, Pleven E, Heidelberger C. The synthesis of 5 fluoro pyrimidines. J Am Chem Soc. 1957; 79:4559–60.
28. Blumenkranz MS, Ophir A, Claflin AJ, Hajek A. Fluorouracil for the treatment of massive periretinal proliferation. Am J Ophthalmol. 1982; 94:458–67.
crossref
29. Abraham LM, Selva D, Casson R, Leibovitch I. The clinical appli cations of fluorouracil in ophthalmic practice. Drugs. 2007; 67:237–55.
30. Yamamoto T, Varani J, Soong HK, Lichter PR. Effects of 5-fluo-rouracil and mitomycin C on cultured rabbit subconjunctival fibroblasts. Ophthalmology. 1990; 97:1204–10.
crossref
31. Singh K, Mehta K, Shaikh NM, et al. Trabeculectomy with intraoperative mitomycin C versus 5-fluorouracil. Prospective randomized clinical trial. Ophthalmology. 2000; 107:2305–9.
32. Suh WJ, Chung WS. Effects of mitomycin C on cultured rabbit osteoblasts. J Korean Ophthalmol Soc. 2001; 42:1464–9.
33. Lee JH, Chung WS, Son JH. The effect of mitomycin C on cultured human osteoblasts. J Korean Ophthalmol Soc. 2003; 44:2122–7.
34. Huang L, Wong YP, Cai YJ. Low dose 5-fluorouracil induces cell cycle G2 arrest and apoptosis in keloid fibroblasts. Br J Dermatol. 2010; 163:1181–5.

Figure 1.
The morphology of cultured human nasal mucosa fibroblasts under phase-contrast microscope. Fibroblasts were treated with various concentrations of MMC for 5 minutes and then incubated. Images are representatives of day 1 of culture. The viable cells were spindle-shaped at all concentrations of MMC. Magnification, ×100. MMC = mitomycin C.
jkos-52-233f1.tif
Figure 2.
The morphology of cultured human nasal mucosa fibroblasts under phase-contrast microscope. Fibroblasts were treated with various concentrations of 5-FU for 5 minutes and then incubated. Images are representatives of day 1 of culture. The viable cells were spindle-shaped at all concentrations of 5-FU. Magnification, ×100. 5-FU=5-fluorouracil.
jkos-52-233f2.tif
Figure 3.
The viability of the cultured human nasal mucosa fibroblasts treated with various concentrations of MMC. Fibroblasts were treated for 5 minutes with MMC (0.01, 0.1, 0.2, 0.4 mg/ml), washed and further incubated for 24 hr. Optical density (OD) of the fibroblasts was measured using MTT assay. Growth rates (%) were calculated as [100 × (OD values of drug-treated cells/OD values of non-treated cells)]. Values and bars represent means of growth rates and the SD, respectively. ∗ p<0.05 compared to non-treated control. MMC = mitomycin C.
jkos-52-233f3.tif
Figure 4.
The viability of the cultured human nasal mucosa fibroblasts treated with various concentrations of 5-FU. Fibroblasts were treated for 5 minutes with 5-FU (0.5, 5, 10, 25 mg/ml), washed and further incubated for 24 hr. Optical density (OD) of the fibroblasts was measured using MTT assay. Growth rates (%) were calculated as [100 × (OD values of drug-treat-ed cells/OD values of non-treated cells)]. Values and bars represent means of growth rates and the SD, respectively. ∗ p<0.05 compared to non-treated control. 5-FU = 5-fluorouracil.
jkos-52-233f4.tif
Figure 5.
Acridine orange/Hoechst (AO/HO) staining of human nasal mucosa fibroblasts after treatment with MMC and 5-FU. Fibroblasts were not-treated (A), or treated with 0.4 mg/ml of MMC (B) and 25 mg/ml of 5-FU (C) for 5 minutes, washed and further incubated for 3 hr. The cells were then stained with AO/HO to identify apoptosis as shown in the Methods. (A) Normal control cells. Arrow indicates blue nuclei and brilliant red cytoplasm. (B) MMC-treated cells. The apoptotic cell shows orange-red nuclei, becoming indistinguishable from the cytoplasm. (C) 5-FU-treated cells. The apoptotic cell shows orange-red nuclei, becoming indistinguishable from the cytoplasm. Magnification, ×400. MMC = mitomycin C, 5-FU = 5-fluorouracil.
jkos-52-233f5.tif
TOOLS
Similar articles